Not Yet RecruitingNot Applicable

A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy

350 participantsStarted 2025-08-06

Plain-language summary

The goal of this study is to develop and refine an integrated minimally invasive care pathway for resectable lung cancer in the immunotherapy era, establishing a novel precision perioperative immunotherapy paradigm encompassing original techniques and clinical applications.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years old;
✓. NSCLC patients underwent radical surgical resection;
✓. Adequate clinical-pathologic data, imaging data and follow-up data obtainable for multi-omics analysis;
✓. Scheduled for or currently receiving neoadjuvant/perioperative immunotherapy.

Exclusion criteria

✕. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems;
✕. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC);
✕. Pregnancy or lactation;
✕. Insufficient sample quality;
✕. Severe organ dysfunction (e.g. cardiac or renal insufficiency);
✕. Other judgments by the Investigator that the patient should not participate in the study.

What they're measuring

Pathological Complete Response (pCR)

Timeframe: At surgery (typically 3-6 months post-treatment initiation)

Trial details

NCT IDNCT07119190

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-06-30

Contact for this trial

Hao Li, MD

+86 13051713494 lihao_pkuhsc@163.com

View on ClinicalTrials.gov More Non-Small Cell Lung Cancer trials